Undernutrition and sarcopenia are associated with a higher incidence of chemotherapy-related toxicity and a poor prognosis in several kinds of cancer, but the impact of sarcopenia on the outcomes of chemotherapy for esophageal cancer remains unclear. Thus, the purpose of this retrospective study was to investigate whether sarcopenia affects the efficacy and toxicities of chemotherapy for advanced esophageal cancer patients. Data were collected from 31 esophageal cancer patients who underwent neo-adjuvant chemotherapy followed by surgery. Body composition was assessed at the start of chemotherapy by bioelectrical impedance analysis, and outcomes of chemotherapy were compared between sarcopenic and non-sarcopenic groups. Of the 31 patients, sarcopenia was observed in 16 (51.6%). The incidence of toxicities was not different between the two groups. However, as for pathologic response, a good therapeutic effect (Grade 2 or higher) was more common in the non-sarcopenic group than in the sarcopenic group (53.3% vs. 25.0%). Multivariate analysis showed that sarcopenia was an independent predictor of poor pathological response (odds ratio 8.02; P = 0.037). The results of this study suggest the potential utility of sarcopenia assessment in neoadjuvant patient selection strategies.
Esophageal cancer Sarcopenia Chemotherapy Bioelectrical impedance analysis
This is a preview of subscription content, log in to check access.
This work was supported by the Grant-in-Aid for Scientific Research (KAKENHI C) (16K09274) from the Japan Society for the Promotion of Science (JSPS).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Gertler R, Stein HJ, Langer R. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg. 2011;253:689–98.CrossRefGoogle Scholar
Cruz-Jentoft AJ, Baeyens JP, Bauer JM. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–23.CrossRefGoogle Scholar
Montano-Loza AJ, Meza-Junco J, Prado CM. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012;10:166–73, 173.e1.Google Scholar
Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10:90–9.CrossRefGoogle Scholar
Prado CM, Lieffers JR, McCargar LJ. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629–35.CrossRefGoogle Scholar
Tan BH, Birdsell LA, Martin L. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973–9.CrossRefGoogle Scholar
Sabel MS, Lee J, Cai S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011;18:3579–85.CrossRefGoogle Scholar
van Vledder MG, Levolger S, Ayez N. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg. 2012;99:550–7.CrossRefGoogle Scholar
Awad S, Tan BH, Cui H. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr. 2012;31:74–7.CrossRefGoogle Scholar
Tan BH, Brammer K, Randhawa N. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015;41:333–8.CrossRefGoogle Scholar
Yip C, Goh V, Davies A. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol. 2014;24:998–1005.CrossRefGoogle Scholar
Ishikawa T, Yasuda T, Doi T. The amino acid-rich elemental diet Elental(R) preserves lean body mass during chemo- or chemoradiotherapy for esophageal cancer. Oncol Rep. 2016;36:1093–100.CrossRefGoogle Scholar
Murimwa GZ, Venkat PS, Jin W. Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery. J Gastrointest Oncol. 2017;8:808–15.CrossRefGoogle Scholar
Ida S, Watanabe M, Karashima R. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy. Ann Surg Oncol. 2014;21:3675–9.CrossRefGoogle Scholar
Makiura D, Ono R, Inoue J. Impact of sarcopenia on unplanned readmission and survival after esophagectomy in patients with esophageal cancer. Ann Surg Oncol. 2018;25:456–64.CrossRefGoogle Scholar
Chen LK, Liu LK, Woo J. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014;15:95–101.CrossRefGoogle Scholar
Proctor MJ, Morrison DS, Talwar D. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104:726–34.CrossRefGoogle Scholar
Japan Esophageal Society. Japanese classification of esophageal cancer: Part I: esophagus, 11th ed., vol 14; 2017, 1–36.Google Scholar
Antoun S, Lanoy E, Iacovelli R. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119:3377–84.CrossRefGoogle Scholar
Iritani S, Imai K, Takai K. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J Gastroenterol. 2015;50:323–32.CrossRefGoogle Scholar
Barret M, Antoun S, Dalban C. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer. 2014;66:583–9.CrossRefGoogle Scholar
Prado CM, Baracos VE, McCargar LJ. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920–6.CrossRefGoogle Scholar